GLIOBLASTOMA MULTIFORME STAGE IV

Report on the first patient treated with GC10-100 in the UK, in September 1991

The following patient underwent brain surgery, excising part of her Glioblastoma Multiforme Stage IV brain tumour. A few weeks after surgery, the tumour recurred aggressively. The patient’s critical disabilities prevented her from having food ingested by mouth. She was sent home in September 5, 1991, with no more than a few weeks to live.  This lady became the first patient in the UK, who used GC10-100 preparations, to treat an advanced brain tumour.

She was able to swallow a few teaspoonfuls per day of GC10 that was given to her by introducing it with a syringe directly onto her tongue.

GC10 targeted the tumour directly and was able to induce an immediate and very clear positive response that impressed doctors and nurses caring for this terminally ill patient.

Her husband commented on a video interview with us:
“My doctor, when he saw her about three or four weeks ago, did not give her very much hope of living.., living even..  until now. 
“Her visiting nurse, went in holidays three weeks ago. My wife was in such a bad shape that when the nurse left here on the Saturday, for her holidays, she was in tears..,  because she though she would never see my wife again.”
“She came back from Holidays about a week ago and was very surprised to see all the positive differences and my wife’s improvements.” Her strength alertness and ability to perform movements impressed all her doctor and nurses.

The dramatic and rapid improvement GC10 produced in this advanced cancer patient, encouraged us and gave us faith to continue exploring and researching the GC10-100 for the treatment of advanced cancer.

Most of the compounds used today in chemotherapy, are chemicals that do not have the ability to penetrate the blood brain barrier.

This barrier, is located at the level of endothelium cells, in brain capillaries. It utilizes selective molecular mechanisms, to prevent certain substances present in the blood, from penetrating the cerebrospinal fluid.

T h e b l o o d b r ai n b a rr ie r r e stricts access to the cerebrospinal fluid for most chemotherapeutic agents. However, natural substances and molecules, extracted from organic food, as those present in the GC10-100 preparations, are recognized as “friendly molecules” by the blood brain barrier mechanisms, and can easily penetrate through the barrier. 

The natural anti-tumour substances present in GC10-100, can therefore easily reach the cerebrospinal fluid, where it targets the tumour site, interacting directly with the cancer cells. As a result of this chemical interaction, there is an immediate reduction in tumorigenic activity.

Because of the ability of GC10 to reach the cerebrospinal fluid, it is much more effective than any strong and sophisticated chemotherapeutic agent, unable to cross the blood brain barrier to target areas of the brain where the tumour is located.